A detailed history of Boothbay Fund Management, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 3,600 shares of PCVX stock, worth $307,512. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,600
Holding current value
$307,512
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $118,450 - $136,732
2,575 Added 10.16%
27,919 $1.42 Million
Q2 2023

Aug 14, 2023

SELL
$34.66 - $54.07 $531,441 - $829,055
-15,333 Reduced 37.69%
25,344 $1.27 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $190,707 - $248,177
-5,258 Reduced 11.45%
40,677 $1.52 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $945,342 - $2.2 Million
45,935 New
45,935 $2.2 Million
Q2 2022

Aug 15, 2022

SELL
$17.68 - $26.58 $135,004 - $202,964
-7,636 Reduced 25.14%
22,733 $495,000
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $12,029 - $18,162
689 Added 2.32%
30,369 $733,000
Q3 2021

Nov 15, 2021

SELL
$20.26 - $26.97 $393,874 - $524,323
-19,441 Reduced 39.58%
29,680 $753,000
Q2 2021

Aug 16, 2021

SELL
$16.45 - $24.06 $95,574 - $139,788
-5,810 Reduced 10.58%
49,121 $1.11 Million
Q1 2021

May 17, 2021

BUY
$18.66 - $29.16 $479,916 - $749,966
25,719 Added 88.04%
54,931 $1.09 Million
Q4 2020

Feb 12, 2021

BUY
$26.57 - $51.74 $776,162 - $1.51 Million
29,212 New
29,212 $776,000
Q3 2020

Nov 16, 2020

SELL
$26.5 - $55.4 $467,380 - $977,089
-17,637 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$26.15 - $35.45 $461,207 - $625,231
17,637 New
17,637 $558,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.07B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.